FDA approves Amgen's AMJEVITATM for treatment of seven inflammatory diseases
Amgen announced the FDA has approved AMJEVITA™ (adalimumab-atto) across all eligible indications of the reference product, Humira® (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for treatment of seven inflammatory diseases. September 23, 2016